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Abstract
Background: In sub-Saharan Africa, artemisinin-based combination therapy (ACT) and injectable artesunate are the
first-line treatments for uncomplicated and severe Plasmodium falciparum malaria, respectively. However, recent
studies suggest that delayed anaemia is associated with these treatments in non-immune travellers. This paper
aimed to assess the risk factors associated with delayed anaemia after falciparum malaria treatment with
artemisinin-containing drugs in malaria-endemic populations.
Methods: Pooled, individual malaria patient data were extracted from 13 clinical trials performed from 2002 to
2011 in various settings of Mali. Treatment regimens were artemether-lumefantrine, artesunate plus amodiaquine,
artesunate plus sulphadoxine-pyrimethamine, artesunate plus sulphamethoxypyrazine-pyrimethamine, artesunate
plus mefloquine, artesunate-pyronaridine, artesunate monotherapy, chloroquine, sulphadoxine-pyrimethamine,
amodiaquine and sulphadoxine-pyrimethamine plus amodiaquine. Univariate and multivariate analyses were
performed using the generalized linear and latent mixed model procedures to assess risk factors associated with
haemoglobin concentration evolution and anaemia during the treatment follow-up.
Results: A total of 5,990 participants were recruited and followed from day 0 to day 28. The participants’ median
age was five years, ranging from three months to 70 years. There was a decrease in haemoglobin level on day 7 in
all treatment arms, but the magnitude varied across treatments. There was a significant risk of haemoglobin level
decrease on day 7 in the artemisinin-based therapy compared to the non-artemisinin treatments. The risk of
haemoglobin concentration drop was associated with age group < five years old (0.61 g/dL 95% CI (0.71 to 0.51),
p < 0.001), baseline high parasite density (0.43 g/dL 95% CI (0.51 to 0.35), p < 0.001) and treatment failure (0.40 g/dL
95% CI (0.59 to 0.20), p = 0.018), while high haemoglobin level at baseline was a protective factor (0.53 to 0.59)
p < 0.001). No association was found between artemisinin-based therapy and severe delayed anaemia.
Conclusions: Oral artemisinin derivative treatments for uncomplicated P. falciparum malaria are associated with a
transient and clinically moderate haemoglobin decrease by day 7 but not associated with a delayed severe anaemia.
Keywords: Uncomplicated, Plasmodium falciparum, Malaria, Delayed anaemia, Artemisinin, Clinical trials
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Background
According to the World Health Organization (WHO) 2013
report, 207 million cases of malaria were estimated to have
occurred in 2012 with 627,000 deaths [1]. Early diagnosis
and treatment of malaria reduce disease progression, pre-
vent deaths and contribute to reduce malaria transmission
[2]. To counter the threat of resistance of Plasmodium
falciparum to monotherapy, and to improve treatment
outcome, WHO recommends the use of artemisinin-based
combination therapy (ACT) for the treatment of uncom-
plicated P. falciparum malaria [3], and the injectable arte-
sunate as the first-line treatment of severe malaria [4].
However, recent data, mainly from case reports raised con-
cerns about possible delayed anaemia associated with arte-
misinin derivative treatments [5-9]. WHO recognized that
post-treatment haemolytic anaemia was not specific to a
particular injectable artesunate formulation and that an-
aemia was also described following the use of intramuscu-
lar artemether and oral artemether-lumefantrine [10,11].
Therefore, WHO called for the systematic monitoring of
haemoglobin after malaria treatment initiation up to one
month.
There is limited large-scale data in the literature from
malaria-endemic areas assessing haematological parame-
ters, particularly anaemia among patients treated with
the artemisinin-containing malaria treatments. Recently
a publication from a large-scale, pooled, multi-country
study data from malaria-endemic areas assessed haem-
atologic parameter changes in patients treated with ACT
(artesunate-amodiaquine, artesunate plus sulphadoxine-
pyrimethamine, dihydro-artemisinin-piperaquine and
artemether-lumefantrine) and other therapy (artesunate,
amodiaquine and sulphadoxine-pyrimethamine plus
amodiaquine) [12]. That study found more anaemia ad-
verse events in the artemisinin-based therapy compared
to the non-artemisinin therapy at the 28th day of follow-
up, but did not provide the specific day of the occurrence
of anaemia during the follow-up period. As precise know-
ledge of the specific occurrence day of haemoglobin
change or anaemia occurrence is of clinical relevance, this
paper aimed to perform a pooled analysis of data from 13
clinical trials conducted in Mali. The goal of this pooled
data analysis was to describe the dynamics of haemoglobin
levels, delayed anaemia and the associated risk or protect-
ive factors during each follow-up day, up to 28 days.
Methods
Data source
A pooled, malaria-treatment, clinical trial analysis was
performed, using individual data extracted from clinical
trial databases of 13 trials conducted by researchers from
Malaria Research and Training Centre (MRTC), Bamako,
a research institution within the University of Sciences,
Techniques and Technologies of Bamako (USTTB), Mali.
The different studies were performed from 2002 to 2011
in various malaria-transmission settings of Mali [13-23]
(Ouologuem D et al. Host immunological factors involved
in clearance of drug resistant falciparum malaria, unpub-
lished observation; Maiga H et al. Dhfr-dhps quadruple
mutant predicts sulfadoxine-pyrimethamine resistance in
Mali, an emerging sulfadoxine-pyrimethamine resistance
setting, unpublished observation).
Treatment regimens
The different malaria treatment regimens were: (i) ACT:
artemether-lumefantrine ((AL) Coartem® from Novartis);
artesunate plus amodiaquine ((AS-AQ), loose or fixed-dose
combination, Arsucam/Coarsucam®, both from Sanofi-
Aventis); artesunate plus sulphadoxine-pyrimethamine
((AS-SP), loose combination; AS, Arsumax® from Sanofi-
Aventis and SP, Fansidar® from Roche); artesunate plus
sulphamethoxypyrazine-pyrimethamine ((AS-SMP), loose
combination, Coarinate® from Dafra Pharma); artesunate
plus mefloquine ((AS-MEF), loose combination, Artequin®
from Mepha Pharma); and, artesunate-pyronaridine
((AS-PYR), fixed-dose combination, Pyramax® from Shin
Poong); (ii) artesunate oral monotherapy ((AS), Arsumax®
or Asunate Denk® respectively from Sanofi-Aventis and
Denk Pharma); (iii) non ACT: chloroquine (CQ); amodia-
quine (AQ); sulphadoxine-pyrimethamine (SP) and sulpha
doxine-pyrimethamine plus amodiaquine ((SP-AQ), loose
combination).
Treatment courses durations were three days for all
except for: a) SP given as a single dose; and, b) AS given
up to five days in one study [21] and seven days in
another study [13]. The treatment doses were given by
the study investigators and details are provided in each
study reference [13-23] (Ouologuem D et al. Host
immunological factors involved in clearance of drug re-
sistant falciparum malaria, unpublished observation;
Maiga H et al.: Dhfr-dhps quadruple mutant predicts
sulfadoxine-pyrimethamine resistance in Mali, an emerging
sulfadoxine-pyrimethamine resistance setting, unpublished
observation) and also in a Additional file 1.
Outcome definitions
Data were systematically analysed according to three
outcomes: dynamic of haemoglobin level, haemoglobin
drop and anaemia occurrence.
Haemoglobin levels were analysed as a continuous vari-
able (haemoglobin changes outcome) and as categorical
variables (haemoglobin drop and anaemia occurrence).
Drop of haemoglobin value was defined from day 0 to the
day of the different follow-up visit (day 7, 14, 28) with the
following thresholds: ≥1 g/dL or ≥2 g/dL. Anaemia was
defined as a haemoglobin value <10 g/dL and severe an-
aemia as haemoglobin value <8 g/dL as described else-
where [12]. Delayed anemia was defined as an anaemia
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(severe or not) observed any time of follow-up from day 7
to day 28 [5].
For these outcomes, multivariate analyses assessed the
different associated risk factors during each visit after treat-
ment (day 7, 14 or 28) in order to determine any significant
changes during the follow-up. These analyses included all
participants for whom haemoglobin data were available on
day 0 and at least one follow-up day (day 7 or 14 or 28).
Specifically for the delayed severe anaemia occurrence, as-
sociated risk factors were assessed with different time
points: (i) from day 7 to day 28; (ii) from day 14 to day 28;
and, (iii) on day 28. These analyses used a subset of partici-
pants for which the haemoglobin data were available for all
follow-up visits (day 0, 7, 14, and 28). Different late or de-
layed severe anaemia periods were assessed: (i) an absence
of severe anaemia on day 0 followed by its occurrence dur-
ing any subsequent days for follow-up (7 or 14 or 28); (ii)
an absence of severe anaemia on day 0 and day 7 followed
by its occurrence during any subsequent days for follow-up
(i.e., day 14 or 28); and, (iii) an absence of severe anaemia
on day 0 and day 7 and day 14 followed by its occurrence
on day 28.
Statistical analysis
Descriptive statistics provided the total number of partici-
pants, means, standard deviations, medians, minimums,
and maximums for quantitative variables and proportions
for qualitative variables.
Univariate analyses assessed the haemoglobin changes
between day 0 and the day of post-treatment evaluation
(day 7, 14 or 28) using paired Student test in each treat-
ment arm.
For both continuous variable of haemoglobin changes
and categorized variable of haemoglobin drop or anaemia
outcomes, multivariate analyses were performed using
generalized linear and latent mixed model (GLLAMM),
with study site as a latent factor and as random effect.
Models were systematically adjusted for covariates such as
age, parasite density at baseline (log transformed), malaria
treatment, and treatment failure during the follow-up. For
the haemoglobin changes outcome, the gaussian family
(with the identity canonical link) was used to estimate the
coefficients of covariate effects. For the categorized
haemoglobin drop and anaemia outcomes, the binomial
family (the logit canonical link) was used to estimate odds
ratios associated with covariates.
The confidence intervals (CIs) were estimated at 95%
and p value <0.05 was considered significant. Data were
analysed with GLLAMM procedure using Stata Software
version 12.1 (Stata Corp).
Ethical issues
Each study had a prior approval from the institutional
ethical committee at the Faculty of Medicine, Pharmacy
and Odonto-Stomatogy (FMPOS)/USTTB, Bamako,
Mali. Written consent was obtained in each study from
each participant or parent/legal guardian.
Results
Study information and baseline characteristics
This pooled data of 13 trials in eight Malian sites (Figure 1)
enrolled 5,990 participants with various malaria treat-
ments (Table 1), including ACT (AL, AS-AQ, AS-SP,
AS-SMP, AS-MEF, AS-PYR; oral AS monotherapy; and,
non ACT (CQ, AQ , SP and SP-AQ).
Table 2 shows that the median age for the pooled data
was five years, ranging from three months to 70 years.
The baseline (day 0) proportion of anaemia was 36% and
the baseline parasite density geometric mean was 17,789
parasites/μl.
Assessment of haemoglobin level per visit day
On day 7: overall, there was an average haemoglobin de-
crease of 0.4 g/dL compared to day 0. Univariate ana-
lyses showed a significant decrease (p < 0.001) in all
treatments except for AQ (Table 3). The frequency of
haemoglobin drop to ≥1 g/dL and to ≥2 g/dL compared
to day 0 was 32.2% (858/2,668) and 11.4% (303/2,668),
respectively.
Multivariate analyses showed a higher risk for haemo-
globin decrease in the ACT (AS or the combined
AS-AQ/AS-SP/AS-PYR and AL) compared to the non
ACT (CQ/AQ/SP). The risk of haemoglobin decrease
was significant for the AS, mean decrease of 0.69 g/dL
95% CI (0.95-0.44), p < 0.001; and the AS-containing
combinations: AS-AQ/AS-SP/AS-PYR, 0.34 g/dL, 95%
CI (0.57-0.11), p = 0.003 (Table 4). A similar trend was
observed for the haemoglobin drop to ≥1 g/dL for AS
and the AS-containing combinations: AS-AQ/AS-SP/
AS-PYR, but was only significant for the AS arm (OR =
1.69, 95%CI (1.31-2.18); p < 0.001) (Table 5). There was
no risk associated with a haemoglobin drop ≥2 g/dL on
day 7 with artemisinin-derivative treatments (Table 6).
There was even a protective effect against haemoglobin
drop ≥2 g/dL with AL (OR = 0.51, 95% CI (0.28-0.90);
p = 0.02) and the AS-containing combinations: AS-AQ/
AS-SP/AS-PYR (OR = 0.70, 95% CI (0.52-0.94); p = 0.02)
compared to non-artemisinin treatments (Table 6).
A significant risk of haemoglobin decrease was associated
with other covariates (Table 4) such as the age group < five
years (p < 0.001), a high parasite density at baseline (p <
0.001), a treatment failure (p = 0.018) and a lower baseline
haemoglobin level ( p < 0.001). There was also a significant
risk of haemoglobin drop ≥1 g/dL and ≥2 g/dL for patients
showing a high parasite density at baseline with OR of 1.56
(95% CI (1.33-1.83); p < 0.001) and 1.80 ((1.41-2.30);
p < 0.001), respectively (Tables 5 and 6).
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Figure 1 Study sites. Study sites are indicated by red dots.
Table 1 Number of patients per study and treatment arm
Study* (year) Treatment
TotalAL AS-AQ AS-PY AS-SP AS-SMP AS-MF AS SPAQ SP AQ CQ
[13] (2010–11) 100 100
UO (2009) 337 337
[14] (2007–08) 44 86 130
[15] (2007) 66 132 198
[16] (2006) 68 135 203
[17] (2005–07) 257 255 259 771
[18] (2005) 133 134 133 400
[19] (2004–05) 235 235 470
[20] (2003–04) 303 303 606
[21] (2002–04) 252 249 251 752
UO (2002–04) 948 948
UO (2002–03) 619 619
[22] (2002–03) 121 115 220 456
Total 1,310 775 218 642 303 235 351 133 740 115 1,168 5,990
*The studies are cited in descending order from conduct year ranging from 2011 to 2002. Numbers in the first column represent publication references as cited in
the text. UO, unpublished observations.
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On day 14: overall, there was an average haemoglobin
increase of 0.13 g/dL compared to day 0. Univariate ana-
lyses in Table 3 showed a relatively small increase of
haemoglobin level on day 14 compared to day 0 in all
treatment arms except for AS-MEF. The frequency of
haemoglobin drop ≥1 g/dL and ≥2 g/dL compared to
day 0 was 21.6% (1,004/4,648) and 8% (371/4,648),
respectively.
The multivariate analysis showed no risk of haemoglobin
decrease or haemoglobin drop ≥1 g/dL, or haemoglobin
drop ≥2 g/dL associated with any of the malaria treatment
arms on day 14 (Tables 4, 5 and 6). However, there was a
Table 2 Baseline characteristics and scheduled hemoglobin evaluation visit per study and site
Study* Site N Haemogobin evaluation days Age median [min, max] P. f. Anaemia prev.
[13] (2010–11) Bougoula- Hameau 100 0, 3, 14, 28 6 [1,11] 28,027 48%
UO (2009) Kolle 77 0, 14, 28 6 [1,18] 44,492 55%
Faladje 88 6 [1,14] 47,942 26%
Bandiagara 100 7 [1, 61] 32,703 28%
Pongonon 72 5 [1, 34] 18,841 43%
[14] (2007–08) Bougoula- Hameau 130 0, 3, 7, 28 6 [2,10] 32,430 31%
[15] (2007) Bougoula- Hameau 198 0, 3, 7, 28 11 [6, 52] 22,115 11%
[16] (2006) Bancoumana 203 0, 7, 14, 28 5 [0.9, 24] 22,183 50%
[17] (2005–07) Bougoula- Hameau 771 0, 7, 14, 28 4 [0.5, 69] 20,463 50%
[18] (2005) Faladje 400 0, 14, 28 36 [6, 60] 23,705 48%
[19] (2004–05) Kambila 470 0, 14, 28 6 [1,70] 18,258 13%
[20] (2003–04) Sotuba 606 0, 28 11 [0.6, 63] 13,592 14%
[21] (2002–04) Bougoula- Hameau 752 0, 3, 7, 14, 28 3 [0.6, 56] 15463 44%
UO (2002–04) Kolle 655 0, 7, 14 7 [0.5, 64] 12200 25%
Bandiagara 293 6 [0.7, 30] 12686 29%
UO (2002–03) Bougoula- Hameau 619 0, 14, 28 3 [0.5, 65] 14897 42%
[22] (2002–03) Kolle 456 0, 7, 14, 28 3 [0.3, 6] 19778 51%
Total 5,990 5 [0.3, 70] 17,789 36%
Note: P. f., Plasmodium falciparum geometric mean; Anaemia prev. (dichotomous variable), anaemia prevalence. Anaemia was defined as haemoglobin
value <10.0 g/dL; Numbers in first column represent publication references as cited in the text.
*The studies are citied in descending order from conduct year ranging from 2011 to 2002. The number given is their publication reference as applicable.
UO, unpublished observations.
Table 3 Haemoglobin changes from baseline to day of follow-up after treatment per treatment arm
Day 0-day 7 Day 0-day 14 Day 0-day 28
N Mean 0 Mean 7 Mean diff, N Mean 0, Mean 14, Mean diff, N Mean 0, Mean 28, Mean diff,
[SD] [SD] (P-value) [SD] [SD] P-value [SD] [SD] (P-value)
AL 193 10.6 [1.7] 10.2 [1.7] −0.4 (<0.001) 861 10.5 [1.9] 10.7 [1.6] +0.2 (0.015) 890 10.7 [1.8] 11.3 [1.6] +0.6 (<0.001)
AS-AQ 403 10.1 [1.8] 9.7 [1.7] −0.4 (<0.001) 729 10.0 [1.7] 10.2 [1.5] +0.2 (<0.001) 667 10.0 [1.8] 10.7 [1.7] +0.7 (<0.001)
AS-PYR 218 11.4 [1.5] 11.0 [1.5] −0.4 (0.001) – – – – 213 11.4 [1.5] 11.9 [1.3] +0.4 (<0.001)
AS-SP 272 10.2 [1.9] 9.7 [1.7] −0.5 (<0.001) 630 10.0 [1.8] 10.1 [1.6] +0.1 (0.023) 610 10.0 [1.8] 10.7 [1.5] +0.7 (<0.001)
AS-SMP – – – – – – – – 105 11.8 [1.8] 12.0 [1.5] +0.2 (0.096)
AS-MEF – – – – 228 11.4 [1.5] 11.2 [1.3] −0.2 0.032 213 11.5 [1.5] 11.9 [1.1] +0.3 (0.0003)
AS 348 10.2 [1.7] 9.5 [1.5] −0.7 (<0.001) 348 10.2 [1.7] 10.3 [1.4] +0.1 (0.198) 297 10.2 [1.8] 11.0 [1.5] +0.8 (<0.001)
SP-AQ – – – – 133 10.0 [1.6] 10.4 [1.5] +0.4 (0.001) 131 10.0 [1.6] 11.1 [1.5] +1.1 (<0.001)
SP 114 10.0 [1.8] 9.4 [1.5] −0.6 (<0.001) 679 10.2 [1.8] 10.3 [1.7] +0.1 (0.102) 706 10.3 [1.8] 10.9 [1.7] +0.6 (<0.001)
AQ 104 9.9 [1.5] 9.7 [1.5] −0.2 (0.3) 62 9.7 [1.6] 9.9 [1.3] +0.2 (0.251) 97 9.9 [1.5] 10.4 [1.6] +0.5 (0.002)
CQ 1016 10.9 [1.9] 10.6 [1.7] −0.3 (<0.001) 978 10.9 [1.9] 11.0 [1.7] +0.1 (0.065) 162 9.86 [1.63] 10.01 [1.54] +0.2 (0.261)
Note: Mean 0, Mean 7, Mean 14, Mean 28 are haemoglobin mean on days 0, 7, 14, and 28, respectively; SD, standard deviation of the mean;
Mean diff, haemoglobin mean on the day of the follow-up minus haemoglobin mean on day 0.
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significant risk of haemoglobin decrease or drop to ≥1 g/dL
or to ≥2 g/dL with a high parasite density at baseline and
the treatment failure (Tables 4, 5 and 6).
On day 28: overall, there was an average haemoglobin
increase of 0.63 g/dL compared to day 0. Univariate ana-
lyses in Table 3 indicate that the increases were signifi-
cant in all treatment arms except for CQ (p = 0.261) and
AS-SMP (p = 0.096). The frequency of haemoglobin
drop ≥1 g/dL and ≥2 g/dL compared to day 0 was 13.9%
(569/4,091) and 4.9% (200/4,091), respectively.
Multivariate analyses showed no risk of haemoglobin
decrease or haemoglobin drop ≥1 g/dL or haemoglobin
drop ≥2 g/dL associated with any malaria treatment arms
on day 28 (Tables 4, 5 and 6). However, there was a signifi-
cant risk of haemoglobin decrease or drop ≥1 or ≥2 g/dL
with treatment failure (Tables 4, 5 and 6), with the higher
risk association for haemoglobin drop ≥2 g/dL (OR: 2.03,
95% CI (1.44-2.87), p < 0.001) (Table 6).
Assessment of anaemia and severe anaemia
Anaemia (haemoglobin <10 g/dL) frequency on day 0, 7,
14, and 28 was 35.5% (2,115/5,957), 45.7% (1,221/2,672),
35.3% (1,640/4,652), and 23.9% (979/4,099), respectively.
The severe anaemia (haemoglobin <8 g/dL) frequency
on day 0, 7, 14, and 28 was, respectively, 9.0% (536/
5,957), 10.1% (269/2,672), 6.2% (286/4,652), and 4.0%
(165/4,099).
Among a total of 1,053 eligible patients (with no se-
vere anaemia on day 0 and haemoglobin data available
on days 0, 7, 14, and 28), 135 patients (12.8%) experi-
enced severe anaemia from day 7 to day 28. Multivariate
analysis showed a risk of severe anaemia associated with
the AS arm from day 7 to day 28 (OR = 1.85 (1.05-3.27);
p = 0.03) compared to the non-artemisinin-contained treat-
ments (CQ alone/AQ alone/SP alone/SP-AQ) (Figure 2).
But, no risk was present with the other artemisinin-
derivative treatments (AL, AS-AQ/AS-SP).
Table 4 Multivariate analysis assessing haemoglobin changes per treatment arm during different post-treatment
follow-up visits
Day 7 (n=2,657) Day 14 (n=4,638) Day 28 (n=4,082)
Covariates** β* (95% CI) p β* (95% CI) p β* (95% CI) p
AL −0.21 (−0.48-0.05) 0.11 −0.06 (−0.17- 0.06) 0.34 −0.05 (−0.18- 0.08) 0.47
AS+partners −0.34 (−0.57- -0.11) 0.003 −0.12 (−0.22- -0.02) 0.02 −0.03 (−0.14- 0.08) 0.62
AS −0.69 (−0.95- -0.44) <0.001 −0.03 (−0.18-0.11) 0.68 0.15 (−0.02-0.32) 0.08
<5 years old −0.61 (−0.71- -0.51) <0.001 −0.62 (−0.71- -0.54) <0.001 −0.51 (−0.60- -0.42) <0.001
Haemo day 0 0.56 (0.53-0.59) <0.001 0.48 (0.46-0.50) <0.001 0.45 (0.43-0.47) <0.001
P. f. day 0 −0.43 (−0.51- -0.35) <0.001 −0.33 (−0.40- -0.026) <0.001 −0.04 (−0.12-0.04) 0.29
Treat fail −0.40 (−0.59- -0.20) 0.018 −0.25 (−0.39- -0.11) <0.001 −0.4 (−0.51- -0.29) <0.001
Note: *β is the regression coefficient estimate obtained from the generalized linear latent and mixed models using site as random effect;
**Covariates references were: CQ, AQ, SP for day 7 and CQ, AQ, SP and SP-AQ for day 14 and day 28 for treatment, the age ≥5 years old for the age group, the
28-day cured parasite outcome after treatment for the treatment failure (Treat fail) outcome, the baseline parasite density was log transformed and treated as
continuous variable; AS + partners were: AS-AQ, AS-SP, AS-PYR for day 7, AS-AQ, AS-SP, AS-MEF for day 14 and AS-AQ, AS-SP, AS-PYR, AS-SMP and AS-MEF for
day 28.
Table 5 Multivariate analysis estimating risk of haemoglobin drop from baseline to ≥1 g/dL during different
post-treatment follow-up visits
Day 7 (2,657) Day 14 (n=4,638) Day 28 (n=4,082)
OR* (95% CI) p OR* (95% CI) p OR* (95% CI) p
Covariates**
AL 0.82 (0.58-1.17) 0.27 1.03 (0.82-1.30) 0.81 1.10 (0.82-1.48) 0.52
AS+partners 1.15 (0.95-1.39) 0.16 0.93 (0.75-1.14) 0.47 1.0 (0.77-1.29) 0.99
AS 1.69 (1.31-2.18) <0.001 0.97 (0.71-1.32) 0.84 1.01 (0.68-1.50) 0.95
<5 years old 0.90 (0.76-1.06) 0.21 0.79 (0.68-0.92) 0.003 0.72 (0.60-0.88) 0.001
P. f. day 0 1.56 (1.33-1.83 <0.001 1.60 (1.38-1.87) <0.001 1.02 (0.85-1.23) 0.81
Treat fail 1.77 (1.24-2.55) 0.002 1.49 (1.14-1.94) 0.003 1.67 (1.32-2.11) <0.001
Note: *OR is the odds ratio obtained from generalized linear and latent mixed model with binomial family using site as random effect;
**Covariates references were: CQ, AQ, SP for day 7 and CQ, AQ, SP and SP-AQ for day 14 and day 28 for treatment, the age ≥5 years old for the age group, the
28-day cured parasite outcome after treatment for the treatment failure (Treat fail) outcome, the baseline parasite density was log transformed and treated as
continuous variable; AS + partners were: AS-AQ, AS-SP, AS-PYR for day 7, AS-AQ, AS-SP, AS-MEF for day 14 and AS-AQ, AS-SP, AS-PYR, AS-SMP and AS-MEF for
day 28.
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Table 6 Multivariate analysis estimating risk of haemoglobin drop from baseline to ≥2 g/dL during different
post-treatment follow-up visits
Day 7 (2,657) Day 14 (n=4,638) Day 28 (n=4,082)
OR* (95% CI) p OR*(95% CI) p OR* (95% CI) p
Covariates**
AL 0.51 (0.28-0.90) 0.02 1.33 (0.95-1.87) 0.10 0.86 (0.54-1.39) 0.55
AS+partners 0.70 (0.52-0.94) 0.02 0.95 (0.69-1.32) 0.78 0.96 (0.63-1.44) 0.83
AS 1.36 (0.97-1.92) 0.08 0.99 (0.61-1.59) 0.96 1.07 (0.58-1.96) 0.83
<5 years old 0.87 (0.68-1.11) 0.25 0.82 (0.65-1.04) 0.10 0.82 (0.60-1.12) 0.21
P.f. day 0 1.80 (1.41-2.30 <0.001 1.68 (1.33-2.12) <0.001 1.30 (0.96-.75) 0.09
Treat fail 1.43 (0.88-2.32) 0.15 1.63 (1.13-2.38) 0.01 2.03 (1.44-2.87) <0.001
Note: *OR is the odds ratio obtained from generalized linear and latent mixed model with binomial family using site as random effect;
**Covariates references were: CQ, AQ, SP for day 7 and CQ, AQ, SP and SP-AQ for day 14 and day 28 for treatment, the age ≥ 5 years old for the age group, the
28-day cured parasite outcome after treatment for the treatment failure (Treat fail) outcome, the baseline parasite density was log transformed and treated as
continuous variable; AS + partners were: AS-AQ, AS-SP, AS-PYR for day 7, AS-AQ, AS-SP, AS-MEF for day 14 and AS-AQ, AS-SP, AS-PYR, AS-SMP and AS-MEF for
day 28.
Figure 2 Multivariate analysis estimating late severe anaemia occurrence risk among patients who participated to all haemoglobin
evaluation from day 0, 7, 14, and 28. n = 1,053, 956 and 941, respectively, for patients who participated to severe anaemia evaluation from day
7 to day 28, day 14 to day 28, and day 28. AL, artemether-lumefantrine; AS-AQ/AS-SP, artesunate plus amodiaquine/artesunate plus sulphadoxine-
pyrimethamine; AS, artesunate; <5 years, <5 years old; PfDay0, Log Plasmodium falciparum density on day 0; TreatFail, Treatment failure outcome.
Odds ratio were obtained from generalized linear and latent mixed model with binomial family using site as random effect; Covariates references
were: CQ, AQ and SP for treatment, the age ≥5 years old for the age group, the 28-day cured parasite outcome after treatment for the treatment
failure outcome, the baseline parasite density was log transformed and treated as continuous variable.
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Multivariate analyses showed no risk of severe anaemia
associated with artemisinin-derivative treatment arms (AS,
AL, AS-AQ/AS-SP) compared to the non-artemisinin-
contained treatments (CQ alone/AQ alone/SP alone/SP-
AQ) from day 7 to day 28 (Figure 2).
Among a total of 956 eligible patients (with no severe an-
aemia before day 14 and haemoglobin data available on
days 0, 7, 14, and 28), 38 patients (4%) experienced severe
anaemia from day 14 to day 28. Multivariate analyses
(Figure 2) showed no risk of severe anaemia associated with
artemisinin-derivative treatment arms (AS, AL, AS-AQ/
AS-SP) compared to the control non-artemisinin-contained
treatments (CQ alone/AQ alone/SP alone/SP-AQ) from
day 14 to day 28.
Among a total of 941 patients (with no severe anaemia
before day 28 and haemoglobin data available on days 0, 7,
14, and 28), 23 patients (2.4%) experienced severe anemia
on day 28. Multivariate analyses (Figure 2) showed no risk
of severe anaemia associated with the artemisinin-
derivative treatment arms (AS, AL, AS-AQ/AS-SP) com-
pared to the control non-artemisinin-contained treatments
(CQ alone/AQ alone/SP alone/SP-AQ) on day 28.
The risk of blood transfusion was assessed: a total of five
cases of blood transfusion were documented, all in chil-
dren ≤ three years old. Transfusion was done based both
on low haemoglobin and clinical anaemia symptoms as
judged by the physician. There were three in AS-AQ arm
(one on day 2, one on day 3 and one on day 31), one in AS
arm (on day 7) and one in SP arm (unknown day). Data of
these patients were excluded from this analysis once they
received the blood transfusion. The transfusion information
was not available for one study (Maiga H et al. Dhfr-dhps
quadruple mutant predicts sulfadoxine-pyrimethamine re-
sistance in Mali, an emerging sulfadoxine-pyrimethamine
resistance setting, unpublished observation) conducted in
2002–2004, which enrolled 948 patients in CQ arm.
Discussion
The study found no evidence of delayed anaemia risk as-
sociated with oral artemisinin derivatives. However, a
moderate haemoglobin decrease or drop on day 7 was
found. There were also risk factors associated with an-
aemia or haemoglobin decrease, such as treatment failure
or high parasite density.
There are limited large-scale data addressing specifically
haemoglobin changes or anaemia occurrence after oral
artemisinin-derivative treatments. Recently, WHO recog-
nized post-treatment haemolytic anaemia with artemisinin
derivatives [10,11] and, therefore, called for the monitor-
ing of haemoglobin as these data came from report cases
from non-endemic malaria populations. This present
study pooled individual data from 13 distinct studies
involving 5,990 participants, of all age groups, from Mali,
West Africa. The use of various artemisinin-containing
treatments, including ACT and non-ACT offered the op-
portunity for comparison of haemoglobin changes or drop
between different malaria treatments.
The baseline anaemia frequency was 36% and varied
across the sites. It was lower than from a study [12], which
reported an average frequency of 60% with pooled multi-
country data, including part of data from Mali on artemi-
sinin derivatives, which are also included in this study.
This study documented a transient and clinically moder-
ate but significant decrease of haemoglobin on day 7 after
treatment initiation in almost all malaria treatments. This
finding was consistent with previous studies [24,25]. Mech-
anisms of anaemia or haemoglobin decrease following mal-
aria episode are multiple, and are not fully understood.
Various causes include haemolysis from malaria itself or
from parasitized and non-parasitized red cells by the im-
mune system or even from auto haemolysis mechanism
[26,27]. Day 7 analysis, after adjusting for covariates (multi-
variate analysis) indicated that some ACT (AS or the com-
bined AS-AQ/AS-SP/AS-PYR) compared to the non-ACT
(CQ/AQ/SP) and covariates (age group < five years, high
parasite density at baseline and treatment failure) were
associated with higher haemoglobin decrease. Another
study reported that younger age, high parasite density at
baseline, and treatment failure were associated with the risk
of post-treatment anaemia [12].
On day 14 and 28 there was significant increase in
haemoglobin in most of treatment arms with maximum in-
crease on day 28. The multivariate analyses indicated that
ACT was not more associated with the risk of haemoglo-
bin drop compared to non-ACT, while other covariates
(such as treatment failure) were associated with the risk of
haemoglobin drop. As reported in this study, haemoglobin
increase or anaemia recovery, which is common by day 28,
was also documented in several studies [12,24,25].
The frequency of severe anaemia, which was about 9%
on day 0 and 10% on day 7, decreased gradually to 4% by
day 28. Multivariate analyses indicated that there was a
risk of severe anaemia associated with the AS arm from
day 7 to day 28, compared to the non-ACT (CQ/AQ/SP/
SP + AQ). But this was not evident from day 14 to 28 or
on day 28. These observations could be explained by the
relatively important decrease of haemoglobin shown in
this study on day 7 particularly with AS arm (Table 3).
Artemisinin derivatives have been shown to induce reticu-
locytopaenia in preclinical studies, potentially by suppress-
ing the erythroblasts [27]. Although the reticulocytes have
not been reported in this study, the relatively moderate
and transient drop of haemoglobin, noted mainly on day 7,
and the increase of haemoglobin from day 14 to day 28 sug-
gest that oral artemisinin derivatives therapy may not have
late clinically relevant deleterious effect on haemoglobin.
Following the previous study reporting anaemia without
haemoglobin evolution assessment [12], this study had an
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advantage of reporting haemoglobin evolution using a
relatively large pooled malaria treatments database, in-
cluding ACT, AS monotherapy and other non-artemisinin
derivatives monotherapy, such as CQ, AQ and SP from
various locations in Mali.
This study could not investigate the mechanisms in-
volved in the haemoglobin evolutions observed. Indeed,
the decrease on day 7 needs more study to improve the
understanding of anaemia mechanisms, such as the reticu-
locytes evaluation. There is also a need for malaria treat-
ment data from various countries, injectable AS treatment,
vulnerable groups (pregnant women, HIV-infected sub-
jects, patients with haemoglobinopathy, etc.).
Conclusions
No association was found between ACT and severe de-
layed anaemia. Oral artemisinin derivative treatments for
uncomplicated P. falciparum malaria are associated with a
transient and clinically moderate haemoglobin decrease
by day 7 but not associated with a delayed severe anaemia.
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